checkAd
    Matinas BioPharma Holdings Aktie
    0,1734
     
    EUR
    +1,70 %
    +0,0029 EUR
    Letzter Kurs 30.04.24 Tradegate
    0,1618
     
    EUR
    9.265 STK
    Geldkurs 08:41:47
    0,1788
     
    EUR
    8.385 STK
    Briefkurs 08:41:47
    ISIN: US5768101058 · WKN: A2DMQP · SYM: 6LJ · USA

    Neueste Nachrichten

    In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
    30.04.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Prices $10 Million Registered Direct Offering
    03.04.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
    27.03.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
    25.03.24 · globenewswire · Matinas BioPharma Holdings
    Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
    22.03.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
    22.03.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
    26.02.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
    20.02.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma to Present at Biotech Showcase 2024
    03.01.24 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
    27.12.23 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
    21.12.23 · globenewswire · Matinas BioPharma Holdings
    Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
    07.11.23 · globenewswire · Matinas BioPharma Holdings